HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
p8jtHVX4mmaF8yNn